Sugi Predict

Sugi Predict / Targets / DUSP10

DUSP10

Dual specificity protein phosphatase 10 · Q9Y6W6 · DUSP10 on Sugi Atlas →

604 patent compounds predicted against DUSP10, 326 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL22608783 SCHEMBL22608783 1.00 14/20
SCHEMBL22608798 SCHEMBL22608798 1.00 14/20
SCHEMBL30419386 SCHEMBL30419386 1.00 14/20
SCHEMBL30419463 SCHEMBL30419463 1.00 14/20
SCHEMBL24339749 SCHEMBL24339749 0.71 14/20
SCHEMBL22608786 SCHEMBL22608786 1.00 13/20
SCHEMBL22608778 SCHEMBL22608778 0.78 13/20
SCHEMBL24339471 SCHEMBL24339471 0.57 13/20
SCHEMBL22608851 SCHEMBL22608851 1.00 12/20
SCHEMBL30419466 SCHEMBL30419466 1.00 12/20
SCHEMBL22608821 SCHEMBL22608821 0.71 12/20
SCHEMBL31161845 SCHEMBL31161845 0.71 12/20
SCHEMBL25630450 SCHEMBL25630450 0.69 12/20
SCHEMBL25630479 SCHEMBL25630479 0.67 12/20
SCHEMBL22608792 SCHEMBL22608792 0.67 12/20
SCHEMBL31161895 SCHEMBL31161895 0.67 12/20
SCHEMBL24339474 SCHEMBL24339474 0.64 12/20
SCHEMBL24339461 SCHEMBL24339461 0.62 12/20
SCHEMBL24339746 SCHEMBL24339746 0.62 12/20
SCHEMBL22608777 SCHEMBL22608777 1.00 11/20

Clinical trials — most relevant to DUSP10 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma PHASE4UNKNOWN
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer PHASE1/PHASE2WITHDRAWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes PHASE2COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer PHASE1/PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer PHASE2COMPLETED
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis PHASE1/PHASE2COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer PHASE2COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120 PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Quantification of GADD34 Expression in RA nanCOMPLETED
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing nanRECRUITING
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients. nanCOMPLETED
Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997 nanCOMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia nanUNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
IVF Outcome in Polycystic Ovary Syndrome Patients nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a DUSP10 binder may also engage these)

ProteinNameSimilarity
Q0IID7 — 1.000 Q0IID7 →
Q9ESS0 — 1.000 Q9ESS0 →
Q9VVW5 — 0.986 Q9VVW5 →
Q9DBB1 — 0.984 Q9DBB1 →
DUSP6 Dual specificity protein phosphatase 6 0.983 landscape →
Q2KJ36 — 0.982 Q2KJ36 →
Q64346 — 0.982 Q64346 →
CDC14A Dual specificity protein phosphatase CDC14A 0.981 landscape →
V6CIV8 — 0.980 V6CIV8 →
P20483 — 0.980 P20483 →
F1QLY4 — 0.980 F1QLY4 →
O88907 — 0.979 O88907 →
Q62767 — 0.979 Q62767 →
Q90W58 — 0.979 Q90W58 →
Q60695 — 0.978 Q60695 →
Q9XSB5 — 0.978 Q9XSB5 →
Q6NTY8 — 0.978 Q6NTY8 →
P45446 — 0.978 P45446 →
Q9TU15 — 0.978 Q9TU15 →
P70600 — 0.978 P70600 →
E9PUQ8 — 0.977 E9PUQ8 →
Q99KY4 — 0.977 Q99KY4 →
P97874 — 0.977 P97874 →
Q63340 — 0.977 Q63340 →
P25799 — 0.977 P25799 →
Q95171 — 0.977 Q95171 →
Q9XSW2 — 0.977 Q9XSW2 →
Q91Z46 — 0.977 Q91Z46 →
Q9NZL6 — 0.977 Q9NZL6 →
NFKB1 Nuclear factor NF-kappa-B p105 subunit 0.977 landscape →